Skip to main content
OpenTrials
Completed

NCT Number: NCT00090051

FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients

The purpose of this study is to provide treatment for patients who have chronic lymphocytic leukemia (CLL), and to compare the use of rituximab added to fludarabine+cyclophosphamide (FC) with FC alone, to determine if rituximab lengthens the time a patient remains free of leukemia symptoms.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Lymphocytic Leukemia Chronic Disease Disease Attributes Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, B-Cell Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Concord Repatriation General Hospital; Haematology, Sydney, New South Wales, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years
  • Established diagnosis of B-cell CLL by NCI Working Group criteria
  • ≤1 previous line of chemotherapy
  • Expected survival >6 months
  • Acceptable hematologic status, liver function, renal function, and pulmonary function
  • Negative serum pregnancy test for both pre-menopausal women and for women who are < 2 years after the onset of menopause
  • Written informed consent

Exclusion criteria

  • Prior treatment with interferon, rituximab or other monoclonal antibody
  • Prior allogeneic bone marrow transplant (BMT) or autologous BMT or peripheral stem cell transplant (PBSCT) or patients who are considered to be candidates for allogeneic or autologous BMT or PSCT as assessed by their treating physician
  • Fertile men or women of childbearing potential not using adequate contraception
  • Severe Grade 3 or 4 non-hematological toxicity or prolonged (> 2 weeks) Grade 3 or 4 cytopenia on prior fludarabine or nucleoside analogue regimen
  • History of fludarabine-induced or clinically significant autoimmune cytopenia
  • History of other malignancies within 2 years prior to study entry, except for adequately treated carcinoma in situ of the cervix; basal or squamous cell skin cancer; low-grade early stage localized prostate cancer treated surgically with curative intent; good prognosis ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone with curative intent.
  • Medical conditions requiring long term use (> 1 month) of systemic corticosteroids
  • Active bacterial, viral, or fungal infection requiring systemic therapy
  • Severe cardiac disease
  • Seizure disorders requiring anticonvulsant therapy
  • Severe chronic obstructive pulmonary disease with hypoxemia
  • Uncontrolled diabetes mellitus or hypertension
  • Transformation to aggressive B-cell malignancy.
  • Known infection with HIV, HCV, or hepatitis B
  • Treatment with any other investigational agent, or participation in another clinical trial within 30 days prior to entering this study
  • Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins
  • Any co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent

Treatment and study plan

Rituximab

Drug

Intravenous repeating dose

fludarabine phosphate

Drug

Intravenous repeating dose

Cyclophosphamide

Drug

Intravenous repeating dose

Primary outcomes

  1. Progression-free Survival (PFS) as Assessed by the Independent Review Committee (IRC)

    Time frame: Mean observation time at time of analysis was approximately 26 months

    Progression-free survival as assessed by the IRC was defined as the time between randomization and the date of first documented disease progression, relapse after response, or death from any cause, whichever came first. Patients without a PFS event were censored at their last tumor assessment date.

  2. Number of Participants With Progression-free Survival (PFS) Events Assessed by the Independent Review Committee (IRC)

    Time frame: Mean observation time at time of analysis was approximately 26 months

    Progression-free survival as assessed by the IRC was defined as the time between randomization and the date of first documented disease progression, relapse after response, or death from any cause (PFS events), whichever came first. Patients without a PFS event were censored at their last tumor assessment date.

  3. Final Analysis: Time to Progression-Free Survival Event

    Time frame: Median observation time was approximately 5 years

    Time to progression-free survival (PFS) event was defined as the time between randomization and the date of first documented PFS event: disease progression, relapse or death by any cause, whichever came first.

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Mean observation time at time of analysis was approximately 26 months

    Overall survival was determined from the date of randomization to the date of death irrespective of cause. Patients who had not died at the time of the final analysis (clinical data cut-off) were censored at the date of the last contact.

  2. Number of Participants With Overall Survival (OS) Events

    Time frame: Mean observation time at time of analysis was approximately 26 months

    Overall survival was determined from the date of randomization to the date of death (OS event) irrespective of cause. Patients who had not died at the time of the final analysis (clinical data cut-off) were censored at the date of the last contact.

  3. Event-free Survival (EFS)

    Time frame: Mean observation time at time of analysis was approximately 26 months

    Event free survival was measured from the day of randomization to the date of first documented PD, relapse after response, start of a new treatment or death from any cause. Patients without an EFS event were censored at their last tumor assessment date.

  4. Number of Participants With Event-free Survival (EFS) Events

    Time frame: Mean observation time at time of analysis was approximately 26 months

    Event free survival was measured from the day of randomization to the date of first documented Progressive Disease (PD), relapse after response, start of a new treatment or death from any cause (EFS events). Patients without an EFS event were censored at their last tumor assessment date.

  5. Disease-free Survival (DFS)

    Time frame: Mean observation time at time of analysis was approximately 26 months

    Disease free survival was defined for all patients with a best overall response (BOR) of Complete Response (CR) and measured the time from first documented CR in a sequence of consecutive CRs until documented disease progression, relapse or death from any cause. Patients without a DFS event at the time of the analysis (clinical data cut-off) were censored at their last tumor assessment date.

  6. Number of Participants With Disease-free Survival (DFS) Events

    Time frame: Mean observation time at time of analysis was approximately 26 months

    Disease free survival was defined for all patients with a best overall response (BOR) of Complete Response (CR) and measured the time from first documented CR in a sequence of consecutive CRs until documented disease progression, relapse or death from any cause (DFS events). Patients without a DFS event at the time of the analysis (clinical data cut-off) were censored at their last tumor assessment date.

  7. Final Analysis: Time to Overall Survival Event

    Time frame: Median observation time was approximately 5 years

    Overall survival (OS) was determined from the date of randomization to the date of death (OS event) irrespective of cause.

  8. Final Analysis: Time to Event-Free Survival Event

    Time frame: Median observation time was approximately 5 years

    Event free survival (EFS) was defined as the time from the day of randomization to the date of first EFS event: documented disease progression, relapse after response, start of a new treatment or death from any cause.

  9. Final Analysis: Percentage of Participants With Complete Response

    Time frame: Median observation time was approximately 5 years

    Complete response was defined as the disappearance of all signs of cancer in response to treatment.

  10. Final Analysis: Time to Disease-Free Survival Event

    Time frame: Median observation time was approximately 5 years

    Time to disease-free survival (DFS) event was defined as the time from first documented response until the first documented DFS event: disease progression, relapse or death from any cause.

  11. Final Analysis: Duration of Response

    Time frame: Median observation time was approximately 5 years

    Duration of response was defined as the time between the date of the earliest qualifying response and the date of disease progression or death due to any cause.

  12. Final Analysis: Time to New Chronic Lymphocytic Leukemia (CLL) Treatment

    Time frame: Median observation time was approximately 5 years

    Time to new CCL treatment was defined as the time from randomization to the first day of new treatment for CCL or death.

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Collaborators

  • Biogen
  • Genentech, Inc.

Registry information

Official study title

Open-label, Multicenter, Randomized, Comparative, Phase III Study to Evaluate the Efficacy and Safety of FCR vs. FC Alone in Previously Treated Patients With CD20 Positive B-cell CLL

Important dates

Study start
2003
Primary completion
2008
Study completion
2012
First posted
Aug 25, 2004
Registry last updated
Aug 1, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.